Gilbert & Cook Inc. Decreases Position in Baxter International Inc (NYSE:BAX)

Gilbert & Cook Inc. lessened its holdings in Baxter International Inc (NYSE:BAX) by 4.9% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,810 shares of the medical instruments supplier’s stock after selling 146 shares during the period. Gilbert & Cook Inc.’s holdings in Baxter International were worth $246,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. 1 North Wealth Services LLC purchased a new stake in shares of Baxter International during the 3rd quarter worth $27,000. Old North State Trust LLC purchased a new stake in shares of Baxter International during the 3rd quarter worth $31,000. Personal Wealth Partners purchased a new stake in shares of Baxter International during the 2nd quarter worth $29,000. TRUE Private Wealth Advisors purchased a new stake in shares of Baxter International during the 2nd quarter worth $29,000. Finally, Evolution Wealth Advisors LLC purchased a new stake in shares of Baxter International during the 2nd quarter worth $32,000. 83.45% of the stock is owned by institutional investors.

NYSE:BAX traded up $0.51 during midday trading on Friday, hitting $78.51. 3,017,392 shares of the company were exchanged, compared to its average volume of 2,768,937. The company has a fifty day simple moving average of $84.08 and a 200 day simple moving average of $82.11. Baxter International Inc has a fifty-two week low of $61.40 and a fifty-two week high of $89.93. The company has a current ratio of 2.78, a quick ratio of 2.10 and a debt-to-equity ratio of 0.72. The company has a market capitalization of $39.56 billion, a PE ratio of 25.74, a price-to-earnings-growth ratio of 2.00 and a beta of 0.97.

BAX has been the subject of several recent analyst reports. UBS Group decreased their price objective on shares of Baxter International from $98.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, October 28th. Credit Suisse Group lifted their price objective on shares of Baxter International from $84.00 to $95.00 and gave the stock an “outperform” rating in a research report on Friday, July 26th. BMO Capital Markets lifted their price objective on shares of Baxter International to $95.00 and gave the stock an “outperform” rating in a research report on Friday, July 26th. Wells Fargo & Co set a $95.00 price target on shares of Baxter International and gave the stock a “buy” rating in a research note on Friday, July 26th. Finally, Piper Jaffray Companies reiterated a “buy” rating on shares of Baxter International in a research note on Tuesday, September 10th. Five research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $90.14.

In other Baxter International news, SVP Andrew Frye sold 3,332 shares of Baxter International stock in a transaction on Monday, October 14th. The shares were sold at an average price of $88.00, for a total value of $293,216.00. Following the transaction, the senior vice president now directly owns 16,391 shares in the company, valued at $1,442,408. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director James R. Gavin III sold 7,950 shares of Baxter International stock in a transaction on Monday, August 19th. The shares were sold at an average price of $87.63, for a total transaction of $696,658.50. Following the completion of the transaction, the director now owns 40,932 shares in the company, valued at $3,586,871.16. The disclosure for this sale can be found here. Insiders have sold a total of 17,396 shares of company stock worth $1,528,575 over the last quarter. 0.70% of the stock is owned by company insiders.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

See Also: Index Funds

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.